CTIS2024-512459-19-00进行中（未招募）1 期
Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in bDMARD-naïve patients with pSoriatic arthriTis
niversitaetsklinikum Erlangen AöR0 个研究点目标入组 129 人开始时间: 2024年3月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Written informed consent obtained from the subject, Adult male or female subject; age = 18 years, Diagnosis of PsA according to CASPAR criteria, SPARCC Enthesitis = 1 at baseline, bDMARD naïve, Failure or adverse reaction to at least one csDMARD or indication to start systemic therapy with Guselkumab due to moderate-to-severe plaques psoriasis, PD Grade = 2 for at least 1 affected enthesis at baseline or PD Grade = 1 for at least 2 affected entheses at baseline
排除标准
- •Diagnosis of any other rheumatological/ immunological disease such as rheumatoid arthritis, SLE, PSS, MCTD, Behcet syndrome or GPA, Concomitant florid active immune mediated disease (e.g. autoimmune hepatitis) that is untreated and/or requires immunosuppressive treatment, History of ongoing, chronic or recurrent infectious disease (Infection with HIV, HBV or HCV) or evidence of tuberculosis infection as defined by a positive QuantiFERON Tb-Gold test. If presence of latent tuberculosis is established then treatment according to local country guidelines must have been initiated but patient cannot take part in the study, History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed), treated or untreated within the past 5 years prior to enrolment, History or evidence of ongoing alcohol or drug abuse, within the last six months prior to enrolment, Contraindication for Guselkumab treatment according to their SmPCs, Use of any inadmissible medication (e.g. drugs under development or bDMARDs approved for PsA other than Guselkumab) List of admitted drugs alongside IMP: • csDMARD - Leflunomide (e.g. Arava), Sulfasalazine (e.g. Azulfidine RA, Pleon RA), Methotrexate (e.g. Lantarel, Metex) and/or • systemic glucocorticoids with a stable dose of = 7,5 mg of prednisolone equivalents within the last 12 weeks of screening, Nursing mother or pregnant woman
研究者
相似试验
进行中（未招募）
1 期
Open-label clinical trial, phase I/IIa, at several study sites to investigate the safety and tolerability of selected deep-frozen immune cells from a donor in patients who underwent a stem cell transplantation, for the enhancement of the immune response, measured as response to an early vaccination. Patients receive a single dose of the study medication after day 120 following the stem cell transplantation. Increasing doses are administered to subsequent groups of patients.Status post allogeneic stem cell transplantationMedDRA version: 19.0Level: LLTClassification code 10067862Term: Allogeneic stem cell transplantationSystem Organ Class: 100000004865EUCTR2012-003033-42-DEniversitätsklinikum Erlangen15
已完成
4 期
Assessment of efficacy and safety of Lipid based Amphotericin B gel 0.1% (Amfy gel®) in patients with moderate to severe vulvovaginal candidiasisCTRI/2014/02/004409Intas Pharmaceuticals Ltd60
已完成
4 期
A study to evaluate the efficacy and safety of vestige spirulina capsules for the immunity in healthy patients.CTRI/2022/09/045585Vestige Marketing Pvt Ltd50
招募中
1 期
A prospective, multicentre open-label clinical trial to evaluate the efficacy of the fixed-dose combination of Doxylamine and Pyridoxine 10/10 mg modified-release capsules on the quality of life of pregnant women presenting with nausea and vomiting of pregnancy (NVP)CTIS2023-505144-19-00Itf Research Pharma S.L.80
已完成
3 期
A clinical trial to study the effect of R-TPR-011 in patients with multiple sclerosisCTRI/2009/091/000655Reliance Life Sciences Pvt Ltd45